Poolbeg Pharma (LON:POLB) Stock Price Down 12.7% – What’s Next?

Poolbeg Pharma PLC (LON:POLB) fell 12.7% during mid-day trading on Thursday . The stock traded as low as GBX 7.50 and last traded at GBX 7.90. Approximately 8,713,230 shares traded hands during mid-day trading, an increase of 332% from the average daily volume of 2,017,350 shares. The stock had previously closed at GBX 9.05.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a report on Thursday.

Poolbeg Pharma Stock Performance

The firm has a market cap of £60.31 million, a P/E ratio of -8.40 and a beta of 1.83. The firm has a 50 day simple moving average of GBX 7.94 and a 200 day simple moving average of GBX 6.35.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.